The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

POSTER
Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia
Author(s):

Peter J. Weiden, MD1; Jelena Kunovac, MD, MS2-4; Shifang Liu, PhD5; Daniel J. Kim, PhD5; James A. McGrory, PhD5

1Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA; 2Redbird Research, Las Vegas, NV, USA; 3Excell Research, Oceanside, CA, USA; 4University of Nevada, Las Vegas, NV, USA; 5Alkermes, Inc., Waltham, MA, USA

Content available until 03/19/2029